(Q40421165)

20 September 2017

1 reference

title

Range of serum cholesterol values in the population developing coronary artery disease (English)

1 reference

20 September 2017

W B Kannel

1

1 reference

PubMed ID

7572691

20 September 2017

language of work or name

English

0 references

publication date

1 September 1995

1 reference

American Journal of Cardiology

20 September 2017

1 reference

20 September 2017

76

1 reference

20 September 2017

69C-77C

1 reference

20 September 2017

9

1 reference

Cholesterol and coronary heart disease. A new era.

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Lipoproteins and atherogenesis. Current concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Serum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Prognostic importance of cholesterol levels after myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Risk of new myocardial infarction in middle-aged men with manifest coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

41-month follow-up of risk factors correlated with new coronary events in 708 elderly patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Doubts about preventing coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Should there be a moratorium on the use of cholesterol lowering drugs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Retardation and arrest of progression or regression of coronary artery disease: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Prognostic significance of progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Atherosclerosis: inhibition of regression as therapeutic possibilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Are we mortgaging the medical profession?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980474-3

10.1016/S0002-9149(99)80474-3

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference

PubMed ID

7572691